35
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Preactive therapeutic drug monitoring (TDM): time to redefine TDM

, &
Received 16 Apr 2024, Accepted 09 May 2024, Published online: 16 May 2024
 

Disclosure statement

K.P.: received lecture fees from Physicians Education Resource LLC and Grifols; scientific advisory board fees: ProciseDx Inc and Scipher Medicine Corporation; and consultant fees from Prometheus Laboratories Inc.; A.S.C.: Consulting: Abbvie, Adiso, Artizan (SAB), Bristol Myers Squibb, Clario, Food is Good, Fresenius Kabi, Fzata, Janssen, Pfizer, Prometheus (SAB), ProciseDx, Spherix, Samsung, Protagonist, Takeda; Speaking (non-branded): Abbvie, BMS; N.M.N.: received educational grants and/or speaker fees from Bristol Myers Squibb, Celltrion, Dr Falk Pharma, Galapagos, Janssen, Lilly, Pfizer, Pharmacosmos, SBK Healthcare, Takeda and Tillotts Pharma AG.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 336.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.